MEMPHIS, Tennessee and MARTINSREID, Germany--Medtronic, Inc. and Scil Technology GmbH have announced a development, licensing and supply agreement between Medtronic and Scil Technology.
The agreement focuses on development of Scil's biologic rhGDF-5 (recombinant human Growth and Differentiating Factor 5) dental regenerative technology for use in bone regeneration for dental implant placement and treatment of periodontal disease.
Under this agreement, Scil Technology is primarily responsible for research and development activities with Medtronic responsible for clinical trials, regulatory approvals and commercialization. Financial terms are not being disclosed.
These regenerative biologics may offer new approaches to saving teeth in patients who are at risk for tooth loss due to periodontal disease and provide new options for other dental procedures for the placement of dental implants. These therapies would be alternative treatments to the traditional bridging procedures performed by dentists.
The therapies derived from this partnership could enable Medtronic to impact the million or more patients each year who are being treated for periodontal disease or seeking dental restoration.
"The partnership with Scil Technology is a continuation of our strategy to expand our biologics portfolio" said Pete Wehrly, senior vice president and president of Medtronic's Spinal and Biologics business. "Scil Technology's therapies have the potential to offer our customers biologic solutions that will expand treatment options for their patients and offer new options for unmet needs in periodontal regeneration."
This agreement strengthens Medtronic's biologic portfolio and will be an important component to Medtronic both in the United States and internationally as the company continues its leadership in expanding indications for therapies utilizing biologics.
"Having completed a Phase I/II clinical trial of our dental regenerative material in Germany, the partnership with Medtronic further strengthens Scil Technology's capability of bringing innovative products to the market. It also advances the company's mission of improving the quality of patients' lives," said Dr. Weishui Weiser, CEO of Scil Technology.
More information about Medtronic and its treatment therapies can be found at Medtronic.
For more information about Scil Technology GmbH, go to Scil Technology GmbH.
To read more about dental bone regeneration, go to dental bone regeneration.
To comment on this topic, go to PennWell Dental Community site.
